Global Viscosupplementation Market Expected To Grow At A CAGR Of Around 8.6%
Growing global prevalence of knee osteoarthritis, demand for minimally invasive procedures, and growing geriatric population are key factors that are expected to drive the viscosupplementation market during the forecast period. In addition, improved healthcare infrastructure and increased awareness of viscosupplementation are expected to provide significant growth in the global viscosupplementation market.
On the other hand, the global viscosupplementation market is expected to be hampered by strict government regulations and increasing denials of insurance for viscosupplementation products.
However, due to the effectiveness of the treatment in relieving patients, the market for viscosupplementation in osteoarthritis of the knee is growing rapidly. Patients who have not recovered from exercise, weight loss, or corticosteroid injections will benefit from viscosupplementation for knee procedures. As a result, it will create an opportunity for market growth.
The global viscosupplementation market is segmented on the basis of product and application. Based on the product, the market is segmented into single injection, three injections and five injections. Further, on the basis of the application, the market is categorized into knee, hip, ankle, and others.
Among the product segments, the three injections segment is expected to experience significant growth in the global viscosupplementation market due to the availability of a large number of marketed products and a high rate of product adoption.
This injection supports the treatment of osteoarthritis, arthritis of the knee is a common form of arthritis that affects many people. It is caused when cartilage, the smooth lining that covers the bones in the joints, breaks down. This injection is suitable for people who have not been relieved by nonsteroidal anti-inflammatory drugs or for people who cannot take medication due to their side effects.
The global viscosupplementation market is further segmented on the basis of geography including North America, Europe, Asia Pacific, and the rest of the world. North America is expected to have a significant share in the global viscosupplementation market due to the increasing incidence of osteoarthritis in the United States and Canada.
The increasing demand for minimally invasive viscosupplementation procedures for the treatment of osteoarthritis of the knee is also responsible for the growth of the market in the region. In addition, the existence of advanced health infrastructure, the presence of major key players and the demand for viscosupplementation products are likely to propel the regional market.
Asia Pacific is expected to experience significant market growth during the forecast period. The growth is attributed to the modernization of healthcare facilities and infrastructure in emerging economies such as China, South Korea, and India.
Furthermore, factors such as increased awareness of the effectiveness of viscosupplementation and the demand for non-surgical procedures are expected to propel the market growth. In addition, the relatively low regulatory barriers in South Korea and other emerging countries are expected to attract industry players seeking to establish a presence in these emerging markets.
Main topics covered:
1. Summary of the report
2. Market overview and information
2.1. Scope of the report
2.2. Analyst analysis and current market trends
2.2.1. Main conclusions
3. Competitive landscape
3.1. Key company analysis
3.1.2. Financial analysis
3.1.3. SWOT analysis
3.2. Key strategy analysis
3.3. Impact of COVID-19 on key players
4. Market determinants
5. Market segmentation
5.1. Global Viscosupplementation Market by Product
5.1.1. Single injection
5.2. Global Viscosupplementation Market By Application
5.2.4. Others (shoulder, spine)
6. Regional analysis
6.1. North America
6.1.1. United States
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.4. South Korea
6.3.5. Rest of Asia Pacific
6.4. Rest of the world
7. Company profiles
7.1. Anika Therapeutics, Inc.
7.2. Ferring BV
7.3. Fidia Farmaceutici SpA
7.4. Johnson & Johnson Services, Inc.
7.5. KalVista Pharmaceuticals, Inc.
7.6. LG Chem (Life Sciences)
7.7. Lifecore Biomedical, LLC
7.8. Maxigen Biotech, Inc.
7.9. Pharmascience Inc. (PendoPharm)
7.10. Regen Lab SA
7.11. Sanofi SA
7.12. Seikagaku Corp.
7.13. Shanghai Haohai Biological Technology Co., Ltd.
7.14. Smith & Neveu SA
7.15. Stellar Pharmaceuticals, Inc.
7.16. Stryker Corp.
7.17. Swiss Biomed Orthopedics SA
7.18. Virchow Biotech Pvt. Ltd.
7.19. Zimmer Biomet Holdings, Inc.
For more information on this report, visit https://www.researchandmarkets.com/r/ssdjf4
Research and markets
Laura Wood, senior
For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets